Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma

To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2002, 17(3), , pp.348-352
Main Authors: Cho, Eun Kyung, Lee, Woon Ki, Lim, Do Yoon, Bang, Soo-Mee, Park, Dong Kyun, Park, Yeon-Ho, Kwon, Oh Sang, Choi, Duck Joo, Shin, Dong Bok, Lee, Jae Hoon, Lee, Tae Hoon
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cisplatin - administration & dosage
Cisplatin - adverse effects
Epirubicin - administration & dosage
Epirubicin - adverse effects
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Humans
Infusion Pumps
Infusions, Intravenous
Male
Middle Aged
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Stomach Neoplasms - secondary
Survival Analysis
의학일반
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50 mg/m(2) intravenous, i.v.) and cisplatin (60 mg/m(2) i.v.) were administered every three weeks during a continuous intravenous infusion of 5-fluorouracil (250 mg/m(2) /day) using infusion pump. One complete response and 19 partial responses (response rate=62%) were achieved. Eight patients remained stable, whereas in four patients the disease progressed. The median duration of response was 22 weeks (95% confidence interval, 18-27 weeks). The median survival for all patients was 10 months (95% confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184 cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%, mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central venous catheter complications that required line removal occurred in 37% (n=13) of the patients. No patient died of toxicity. Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2002.17.3.348